The majority of TP53 mutations in human cancer are missense mutations that commonly occur within the DNA-binding domain of p53 resulting in disruption of p53 DNA-binding activity and impaired ability to regulate target genes and transactivate the p53 antagonist MDM2. Here, TP53 is linked to cancer.